| Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia C Bosc, E Saland, A Bousard, N Gadaud, M Sabatier, G Cognet, T Farge, ... Nature cancer 2 (11), 1204-1223, 2021 | 62 | 2021 |
| Chemotherapy-related reticulate hyperpigmentation: a case series and review of the literature M Masson Regnault, N Gadaud, S Boulinguez, E Tournier, L Lamant, ... Dermatology 231 (4), 312-318, 2015 | 30 | 2015 |
| Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse–Bordeaux … S Bertoli, PY Dumas, E Bérard, L Largeaud, A Bidet, E Delabesse, ... Cancers 12 (4), 773, 2020 | 16 | 2020 |
| Outcome of AML patients with IDH2 mutations in real world before the era of IDH2 inhibitors L Largeaud, E Bérard, S Bertoli, S Dufrechou, N Prade, N Gadaud, ... Leukemia research 81, 82-87, 2019 | 12 | 2019 |
| Real-World Outcomes of Patients with Refractory or Relapsed FLT3-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study PY Dumas, S Bertoli, E Bérard, L Largeaud, A Bidet, E Delabesse, ... Cancers 12 (8), 2044, 2020 | 10 | 2020 |
| More than ten percent of relapses occur after five years in AML patients with NPM1 mutation S Bertoli, S Tavitian, E Bérard, V Mansat-De Mas, L Largeaud, N Gadaud, ... Leukemia & lymphoma 61 (5), 1226-1229, 2020 | 6 | 2020 |
| Outcome of relapsed or refractory acute myeloid leukemia treated with intensive salvage chemotherapy in real life in comparison to intermediate dose cytarabine in phase 3 studies S Bertoli, S Tavitian, E Berard, N Gadaud, I Luquet, A Huynh, A Sarry, ... Leukemia & Lymphoma 60 (1), 238-241, 2019 | 4 | 2019 |
| Azacitidine, intensive chemotherapy or best supportive care in relapsed or refractory acute myeloid leukemia, a DATAML registry study N Gadaud, H Leroy, E Bérard, S Tavitian, T Leguay, S Dimicoli-Salazar, ... Leukemia & lymphoma 63 (6), 1398-1406, 2022 | 3 | 2022 |
| Vitamin C and D supplementation in acute myeloid leukemia PL Mouchel, E Bérard, S Tavitian, N Gadaud, F Vergez, JB Rieu, I Luquet, ... Blood Advances 7 (22), 6886-6897, 2023 | 2 | 2023 |
| Mitochondrial determinants of response and resistance to venetoclax plus cytarabine duplet therapy in acute myeloid leukemia C Bosc, N Gadaud, A Bousard, M Sabatier, G Cognet, E Saland, T Farge, ... BioRxiv, 2020.08. 17.253856, 2020 | 2 | 2020 |
| Outcome of relapsed/refractory AML patients with IDH1R132 mutations in real life before the era of IDH1 inhibitors L Largeaud, S Bertoli, E Bérard, S Dufrechou, N Prade, N Gadaud, ... Leukemia & Lymphoma 61 (2), 473-476, 2020 | 2 | 2020 |
| Is intermediate-dose Cytarabine a good control for patients with relapsed or refractory acute myeloid leukemia? S Bertoli, N Gadaud, S Tavitian, A Sarry, E Bérard, F Huguet, C Recher Blood 128 (22), 3991, 2016 | 2 | 2016 |
| More than 10% of NPM1-mutated AML relapses occur after 5 years from complete remission S Bertoli, S Tavitian, E Berard, N Gadaud, A Sarry, F Huguet, E Delabesse, ... Blood 132, 2802, 2018 | 1 | 2018 |
| L’hyperpigmentation réticulée, une complication méconnue de la chimiothérapie MM Regnault, S Boulinguez, L Lamant, E Tournier, N Gadaud, C Recher, ... Annales de Dermatologie et de Vénéréologie 142 (12), S686, 2015 | 1 | 2015 |
| Dismal outcome of refractory or relapsing patients with myelodysplasia‐related acute myeloid leukemia partially alleviated by intensive chemotherapy H Leroy, N Gadaud, E Bérard, E Klein, I Luquet, JP Vial, JB Rieu, ... Cancer Medicine 13 (3), e7003, 2024 | | 2024 |
| Levofloxacin to Prevent Bacterial Infection in Patients with Acute Myeloid Leukemia Treated By Azacitidine and Venetoclax: A Study from the Dataml Registry X Brousse, N Rasandisona, H Leroy, K Delavigne, N Mottal, S Tavitian, ... Blood 142, 7443, 2023 | | 2023 |
| Improving Patient Selection for Phase I Trials in Hematology: An External Validation of the Gustave Roussy Scoring System at Toulouse University Cancer Institute, Oncopole (IUCT-O) N Gadaud, C Gomez Roca, L Ysebaert, A Perrot, M Estrabaut, ... Blood 140 (Supplement 1), 5045-5046, 2022 | | 2022 |
| " Accelerated phase" chronic lymphocytic leukemia: Still an intermediate risk disease in the era of targeted therapies L Lapierre, C Syrykh, L Largeaud, B Cabarrou, T Filleron, L Oberic, ... Hematological oncology 40 (4), 805-808, 2022 | | 2022 |
| A Case of Hemophagocytic Lymphohistiocytosis Induced by Regorafenib M Jaffrelot, N Gadaud, JP Delord, C Gomez-Roca, S Bétrian Archives of Clinical and Medical Case Reports 5 (1), 96-100, 2021 | | 2021 |
| Azacitidine dans le traitement des leucémies aiguës myéloïdes en rechute ou réfractaires après un cycle de chimiothérapie intensive: étude rétrospective bicentrique sur 526 cas N Gadaud Université Toulouse III-Paul Sabatier, 2020 | | 2020 |
